193 related articles for article (PubMed ID: 36768352)
1. Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor.
Kagabu M; Yoshino N; Murakami K; Kawamura H; Sasaki Y; Muraki Y; Baba T
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768352
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of a third-generation oncolytic herpes simplex viral therapy for an HPV-related uterine cervical cancer model.
Kagabu M; Yoshino N; Saito T; Miura Y; Takeshita R; Murakami K; Kawamura H; Baba T; Sugiyama T
Int J Clin Oncol; 2021 Mar; 26(3):591-597. PubMed ID: 33146805
[TBL] [Abstract][Full Text] [Related]
3. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
4. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Haines BB; Denslow A; Grzesik P; Lee JS; Farkaly T; Hewett J; Wambua D; Kong L; Behera P; Jacques J; Goshert C; Ball M; Colthart A; Finer MH; Hayes MW; Feau S; Kennedy EM; Lerner L; Quéva C
Cancer Immunol Res; 2021 Mar; 9(3):291-308. PubMed ID: 33355229
[TBL] [Abstract][Full Text] [Related]
5. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
6. The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors.
Wang G; Cao J; Gui M; Huang P; Zhang L; Qi R; Chen R; Lin L; Han Q; Lin Y; Chen T; He P; Ma J; Fu R; Hong J; Wu Q; Yu H; Chen J; Huang C; Zhang T; Yuan Q; Zhang J; Chen Y; Xia N
J Exp Clin Cancer Res; 2023 Oct; 42(1):284. PubMed ID: 37891570
[TBL] [Abstract][Full Text] [Related]
7. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
[TBL] [Abstract][Full Text] [Related]
8. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
9. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235
[TBL] [Abstract][Full Text] [Related]
10. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
[TBL] [Abstract][Full Text] [Related]
11. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
[TBL] [Abstract][Full Text] [Related]
12. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
[TBL] [Abstract][Full Text] [Related]
13. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
[TBL] [Abstract][Full Text] [Related]
14. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation.
Sugawara K; Iwai M; Ito H; Tanaka M; Seto Y; Todo T
Mol Ther Oncolytics; 2021 Sep; 22():129-142. PubMed ID: 34514094
[TBL] [Abstract][Full Text] [Related]
16. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
18. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
20. Arenavirus Therapy in Combination with Checkpoint Blockade as an Effective Way for Better Tumour Clearance.
Bhat H; Ali M; Hamdan TA
Cell Physiol Biochem; 2021 Nov; 55(6):726-738. PubMed ID: 34816678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
